Company news

Illumina, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026

October 29, 2026

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2026

October 29, 2026

Illumina To Webcast Upcoming Investor Conference

October 27, 2026

Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery

October 21, 2026

Illumina To Webcast Upcoming Investor Conference

October 20, 2026

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

October 14, 2026

Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

October 8, 2026

Illumina releases SpliceAI2 to help advance rare disease research

October 8, 2026

illumine Ushers in a New Era of Childcare AI with its Latest Launch at illumine NEXT

September 17, 2026

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

July 30, 2026

Illumina expands Billion Cell Atlas program with new AI drug developers

July 16, 2026

Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

July 9, 2026

Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

July 9, 2026

Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

June 23, 2026

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

June 8, 2026

Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

May 28, 2026

Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

May 28, 2026

David P. King elected to Illumina's Board of Directors

May 21, 2026

Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact

May 18, 2026

illumine Sets the Benchmark for Secure AI in Childcare with SOC 2 Type II Certification

May 14, 2026

[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

May 4, 2026

Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

April 30, 2026

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

April 16, 2026

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

April 14, 2026

Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

April 9, 2026

Illumina Announces Changes to Board of Directors

April 1, 2026

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

March 17, 2026

Illumina advances preventive genomics through strategic consortium with Veritas Genetics

March 15, 2026

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

March 4, 2026

Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics

February 26, 2026

Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

February 26, 2026

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

February 25, 2026

Illumina launches TruPath Genome, setting a new standard in genomic insight

February 24, 2026

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

February 23, 2026

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

February 5, 2026

Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

February 3, 2026

PacBio Completes Sale of Short-Read Sequencing Assets

February 2, 2026

Illumina completes acquisition of SomaLogic

January 30, 2026

Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology

January 20, 2026

Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

January 13, 2026

Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

January 12, 2026

Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

January 12, 2026

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

January 11, 2026

Illumina Appoints Dr. Eric Green as Chief Medical Officer

January 8, 2026

Illumina and PREMIA partner to expand clinical access to CGP in Asia

January 8, 2026

Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

January 5, 2026

Illumina To Webcast Upcoming Investor Conference

December 15, 2025

Correction: MyOme, Inc

December 14, 2025

Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study

November 11, 2025

Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks

November 9, 2025

Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 50 decks. Every deck is listed under its year.